Ampelopsin (
AMP), a novel
flavonoid, has been shown to effectively inhibit the proliferation and induce apoptosis of some
prostate cancer and
breast cancer cell lines. Whether
AMP has chemopreventive effects on the cell growth and apoptosis of human
osteosarcoma MG-63 cells remains unknown. In the present study, MG-63 cells were exposed to different concentrations (0, 25, 50, 75, 100 μmol/L) of
AMP for 24, 48, 72 and 96 h and then the cell viability was measured by
CCK-8 assay. The
AMP-induced apoptotic cells were identified by Hochest33258 staining and quantified by
Annexin V-FITC/PI double staining using flowcytometry (FCM). The effect of
ampelopsin (
AMP) on cell cycle was evaluated using PI staining with FCM. The
protein levels of
cyclin A, CDK2 and p21(CIP1) were measured by Western blotting. The cell viability was reduced in a time- and dose-dependent manner after exposure to
AMP atarangeof 20-100 μmol/L. For the treatment of
AMP, increases of apoptotic index and rate were observed in MG-63 cells. The
AMP blocked cells in the G0/G1 phase of the cell cycle. Furthermore,
AMP increased p21(CIP1) expression but decreased
cyclin A and CDK2 expression after
AMP exposure.
AMP inhibited cell growth and induced apoptosis and G0/G1 phase arrest in MG-63 cells in vitro, with the potential mechanism of the negative regulation of cell cycle-related
protein.